Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Target Raised at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target increased by JPMorgan Chase & Co. from $950.00 to $1,050.00 in a report issued on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on REGN. HSBC upped their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners boosted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a report on Thursday, October 8th. Finally, Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $872.00.

Regeneron Pharmaceuticals Price Performance

REGN opened at $927.89 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The firm has a market cap of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $935.35. The stock has a 50-day moving average price of $793.30 and a 200-day moving average price of $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the firm posted $11.83 earnings per share. The business’s revenue was up 36.3% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Insiders Place Their Bets

In related news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $11,358,000. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.